ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

House Committee Aims To Cut Markup On Office-Administered Cancer Drugs.

November 16, 2001

QOL With Femara Comparable To Placebo, Analysis Finds

December 26, 2003

Funding Opportunities: ONS Biotherapy Phase II, Outcomes-Research Grant

August 3, 2001

Obituary: Hayden Braine, 67, Blood Cell Transfusion Pioneer At Hopkins

November 19, 2010

Funding Opportunity: NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators

October 3, 2014

Breast Cancer Strategic Plan Underway Following HHS Secretary’s Conference

January 7, 1994